Datopotamab deruxtecan combinations showed encouraging tumour responses in patients with advanced non-small cell lung cancer in TROPION-Lung02 Phase Ib trial
In previously untreated patients, AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan plus pembrolizumab with or without platinum chemotherapy demonstrated objective response rates of 57% and 50%, respectively, with a disease control rate of 91% across cohorts. Three ongoing pivotal trials are evaluating datopotamab deruxtecan and immune checkpoint inhibitor combinations in 1st-line non-small cell lung cancer .Updated results from the TROPION-Lung02 Phase Ib trial showed that, with additional enrolment